809 Pou4f1 Promotes Braf Inhibitor Resistance by Reactivating Mapk Signaling Pathway in Melanoma

L. Liu,Q. Yue,J. Ma,Q. Shi,C. Li

DOI: https://doi.org/10.1016/j.jid.2019.03.885

2019-01-01

Abstract:Despite there is a nice response rate in BRAF mutant melanoma with BRAF inhibitor, the overwhelming majority of patients eventually develop resistance. Preclinical studies suggest that ERK reactivation is a major resistance mechanism to BRAF inhibitor, the mechanism by which ERK gets phosphorylated was not fully understood. Here, we show that POU class 4 homeobox 1 (POU4F1) is high expression in BRAF mutant melanoma, which leads to hyperproliferation of melanoma by reactivation of MAPK pathway, and finally promote melanoma resistance. Further mechanistic studies showed that POU4F1 is abnormally highly expressed in melanoma tissues, knock down POU4F1 inhibite the proliferation of melanoma, and vice versa. POU4F1 is highly expressed in in BRAF inhibitor-resistant melanoma, and the expression of p-ERK in BRAF inhibitor-resistant cells is also significantly increased. In addition, overexpression of POU4F1 promoted the Phosphorylation of ERK in melanoma, which is confirmed that high expression of POU4F1 promotes the reactivation of ERK, a key downstream molecule of the MAPK pathway, strongly suggesting that POU4F1 mediates melanoma BRAF inhibitor resistance by reactivation of the MAPK signaling pathway. These findings establish POU4F1 as a therapeutic strategy in treatment-resistant BRAF mutant melanoma and provide insight into the mechanism of action.